Head of Department of Immunotherapy
Leiden University Medical Center (LUMC), Netherlands
Email: a.geluk@lumc.nl
VALIDATE Role: Investigator
Research Keywords:
Leprosy, TB, immunology, biomarkers, diagnostic tests, One Health, vaccines
Biography
Geluk’s research focuses on Immunodiagnostics of Leprosy and Tuberculosis including basic-, translational-, applied- as well as field research based on immunological, molecular biological, chemical and epidemiological approaches. The investigations into these two infectious diseases evolve around: Global Health, Population Health, and One Health.
Geluk’s vison is that not only scientific but also societal and philanthropic valorization will result from the research and through collaborations with field sites. Therefore, her research aims at the design of strategies to predict, diagnose, prevent and better treat leprosy and tuberculosis by translation of basic research in immunology and molecular biology to field applications.
Weblinks of interest
Orcid Profile
LinkedIn Profile
Diagnostics | Myco Research Leiden
Mycobacterial Research Leiden
Key Publications
Identification of M. leprae- and Mtb-unique antigens for human Tcells essential to protective immunity or immunopathology:
- Geluk, A, V. Taneja, K.E. van Meijgaarden, E. Zanelli, C. AbouZeid, J.E.R. Thole, R.R.P. de Vries, C.S. David, and T.H.M. Ottenhoff. 1998. Identification of HLA class II-restricted determinants of M. tuberculosis-derived proteins using HLAtransgenic, class II deficient mice. Proc. Natl. Acad. Sci. USA 95:10797-10802. doi: 10.1073/pnas.95.18.10797.
- Geluk A, Klein MR, Franken KL, van Meijgaarden KE, Wieles, B, Pereira KC, Buhrer-Sekula S, Klatser PR, Brennan PJ,Spencer JS, Williams DL, Pessolani MC, Sampaio EP, Ottenhoff TH. Postgenomic approach to identify novel Mycobacterium leprae antigens with potential to improve immunodiagnosis of infection. 2005. Infect. Immun. 73: 5636-5644. doi:10.1128/IAI.73.9.5636-5644.2005.
Development of a live M. tuberculosis challenge model using HLAtransgenic mice to analyse candidate TB vaccines in the context of HLA polymorphism:
- Commandeur, S, SJF van den Eeden, K Dijkman, SO Clark, KE van Meijgaarden, L Wilson, KLMC Franken, A Williams, D Christensen, THM Ottenhoff and A Geluk. 2014. The in vivo expressed Mycobacterium tuberculosis (IVE-TB) antigen Rv2034 induces CD4+ T-cells that protect against pulmonary infection in HLA-DR transgenic mice and guinea pigs. Vaccine 32: 3580-3588. doi: 10.1016/j.vaccine.2014.05.005.
- Coppola M, SJF van den Eeden, N Robbins, L Wilson, KLMC Franken, LB Adams, TP Gillis, THM Ottenhoff, and A Geluk. 2018. Vaccines for Leprosy and Tuberculosis: opportunities for shared research, development and application. Front. Immunol. 9:308. doi: 10.3389/fimmu.2018.00308.
Identification of disease-specific Biomarkers for application in tests for diagnosis and treatment-monitoring of Leprosy and Tuberculosis:
- Geluk A, Bobosha K, JJ vdP-vS, Spencer JS, Banu S, Martins SB,Cho SN, Franken KL, Kim HJ, Bekele Y, Uddin MK, Abdul HS, Aseffa A, Pessolani MC, Pereira GM, Dockrell HM, Ottenhoff TH. New biomarkers with relevance to leprosy diagnosis applicable in areas hyperendemic for leprosy. J Immunol. 2012; 188: 4782-4791. doi: 10.4049/jimmunol.1103452.
- Khadge, S., S. Banu, K. Bobosha, van der Ploeg-van Schip JJ, I. M. Goulart, P. Thapa, C. B. Kunwar, K. E. van Meijgaarden, S. J. van den Eeden, L. Wilson, S. Kabir, H. Dey, L. R. Goulart, J. Lobato, W. Carvalho, Y. Bekele, K. L. Franken, A. Aseffa, J. S. Spencer, L. Oskam, T. H. Ottenhoff, D. A. Hagge, and A Geluk. 2015. Longitudinal immune profiles in type 1 leprosy reactions in Bangladesh, Brazil, Ethiopia and Nepal. BMC. Infect. Dis. 15: 477. doi: 10.1186/s12879-015-1128-0.
- Geluk A, and Corstjens P. CRP: tell-tale biomarker or common denominator? The Lancet Infectious Diseases 2017; 17: 1225-1227. doi: 10.1016/S1473-3099(17)30472-3.
- Tió-Coma M, Kiełbasa SM, van den Eeden SJF, Mei H, Roy JC, Wallinga J, Khatun M, Soren S, Chowdhury AS, Alam K, van Hooij A, Richardus JH, and A Geluk. Blood RNA signature RISK4LEP predicts leprosy years before clinical onset.
|